Siebert Williams Shank initiated coverage on I-Mab with a new price target
$IMAB
Biotechnology: Pharmaceutical Preparations
Health Care
Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $96.00 | Buy | Siebert Williams Shank |
| 11/1/2021 | $83.00 → $85.00 | Buy | Needham |
| 9/1/2021 | $75.00 → $95.00 | Buy | HC Wainwright & Co. |
Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00
Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously
HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously